Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

An iminosugar with potent inhibition of dengue virus infection in vivo.

Perry ST, Buck MD, Plummer EM, Penmasta RA, Batra H, Stavale EJ, Warfield KL, Dwek RA, Butters TD, Alonzi DS, Lada SM, King K, Klose B, Ramstedt U, Shresta S.

Antiviral Res. 2013 Apr;98(1):35-43. doi: 10.1016/j.antiviral.2013.01.004. Epub 2013 Jan 31.

PMID:
23376501
2.

Dengue Virus Evolution under a Host-Targeted Antiviral.

Plummer E, Buck MD, Sanchez M, Greenbaum JA, Turner J, Grewal R, Klose B, Sampath A, Warfield KL, Peters B, Ramstedt U, Shresta S.

J Virol. 2015 May;89(10):5592-601. doi: 10.1128/JVI.00028-15. Epub 2015 Mar 11.

3.

Evaluation of dengue antiviral candidates in vivo in mouse model.

Watanabe S, Vasudevan SG.

Methods Mol Biol. 2014;1138:391-400. doi: 10.1007/978-1-4939-0348-1_24.

PMID:
24696350
4.

Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing.

Frias-Staheli N, Dorner M, Marukian S, Billerbeck E, Labitt RN, Rice CM, Ploss A.

J Virol. 2014 Feb;88(4):2205-18. doi: 10.1128/JVI.03085-13. Epub 2013 Dec 11.

5.

Inhibition of dengue virus by an ester prodrug of an adenosine analog.

Chen YL, Yin Z, Lakshminarayana SB, Qing M, Schul W, Duraiswamy J, Kondreddi RR, Goh A, Xu HY, Yip A, Liu B, Weaver M, Dartois V, Keller TH, Shi PY.

Antimicrob Agents Chemother. 2010 Aug;54(8):3255-61. doi: 10.1128/AAC.00397-10. Epub 2010 Jun 1.

6.

Inhibition of dengue virus through suppression of host pyrimidine biosynthesis.

Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S, Zhou J, Poh MK, Florez de Sessions P, Niyomrattanakit P, Dong H, Hoffmaster K, Goh A, Nilar S, Schul W, Jones S, Kramer L, Compton T, Shi PY.

J Virol. 2011 Jul;85(13):6548-56. doi: 10.1128/JVI.02510-10. Epub 2011 Apr 20.

7.

Testing antiviral compounds in a dengue mouse model.

Schul W, Yip A, Shi PY.

Methods Mol Biol. 2013;1030:269-81. doi: 10.1007/978-1-62703-484-5_21.

PMID:
23821275
8.

Ten years of dengue drug discovery: progress and prospects.

Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, Yokokawa F, Nilar S, Smith P, Beer D, Lescar J, Shi PY.

Antiviral Res. 2013 Nov;100(2):500-19. doi: 10.1016/j.antiviral.2013.09.013. Epub 2013 Sep 27. Review.

PMID:
24076358
9.

Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication.

van Cleef KW, Overheul GJ, Thomassen MC, Kaptein SJ, Davidson AD, Jacobs M, Neyts J, van Kuppeveld FJ, van Rij RP.

Antiviral Res. 2013 Aug;99(2):165-71. doi: 10.1016/j.antiviral.2013.05.011. Epub 2013 Jun 2.

PMID:
23735301
10.

A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for Influenza and Dengue).

Warfield KL, Plummer E, Alonzi DS, Wolfe GW, Sampath A, Nguyen T, Butters TD, Enterlein SG, Stavale EJ, Shresta S, Ramstedt U.

Viruses. 2015 May 13;7(5):2404-27. doi: 10.3390/v7052404.

11.

Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence.

Stein DA, Perry ST, Buck MD, Oehmen CS, Fischer MA, Poore E, Smith JL, Lancaster AM, Hirsch AJ, Slifka MK, Nelson JA, Shresta S, Früh K.

J Virol. 2011 Oct;85(19):10154-66. doi: 10.1128/JVI.05298-11. Epub 2011 Jul 27.

12.

Antiviral activity of four types of bioflavonoid against dengue virus type-2.

Zandi K, Teoh BT, Sam SS, Wong PF, Mustafa MR, Abubakar S.

Virol J. 2011 Dec 28;8:560. doi: 10.1186/1743-422X-8-560.

13.

STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor.

Perry ST, Buck MD, Lada SM, Schindler C, Shresta S.

PLoS Pathog. 2011 Feb;7(2):e1001297. doi: 10.1371/journal.ppat.1001297. Epub 2011 Feb 17.

14.

Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome.

Tuiskunen A, Wahlström M, Bergström J, Buchy P, Leparc-Goffart I, Lundkvist A.

Virol J. 2011 Aug 11;8:398. doi: 10.1186/1743-422X-8-398.

15.

Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines.

Züst R, Toh YX, Valdés I, Cerny D, Heinrich J, Hermida L, Marcos E, Guillén G, Kalinke U, Shi PY, Fink K.

J Virol. 2014 Jul;88(13):7276-85. doi: 10.1128/JVI.03827-13. Epub 2014 Apr 16.

16.

A genetic and pathologic study of a DENV2 clinical isolate capable of inducing encephalitis and hematological disturbances in immunocompetent mice.

Amorim JH, Pereira Bizerra RS, dos Santos Alves RP, Sbrogio-Almeida ME, Levi JE, Capurro ML, de Souza Ferreira LC.

PLoS One. 2012;7(9):e44984. doi: 10.1371/journal.pone.0044984. Epub 2012 Sep 13.

17.

Nordihydroguaiaretic acid (NDGA) inhibits replication and viral morphogenesis of dengue virus.

Soto-Acosta R, Bautista-Carbajal P, Syed GH, Siddiqui A, Del Angel RM.

Antiviral Res. 2014 Sep;109:132-40. doi: 10.1016/j.antiviral.2014.07.002. Epub 2014 Jul 11.

PMID:
25017471
18.

Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo.

Chang J, Schul W, Butters TD, Yip A, Liu B, Goh A, Lakshminarayana SB, Alonzi D, Reinkensmeier G, Pan X, Qu X, Weidner JM, Wang L, Yu W, Borune N, Kinch MA, Rayahin JE, Moriarty R, Xu X, Shi PY, Guo JT, Block TM.

Antiviral Res. 2011 Jan;89(1):26-34. doi: 10.1016/j.antiviral.2010.11.002. Epub 2010 Nov 10.

19.

Mouse models of dengue virus infection and disease.

Yauch LE, Shresta S.

Antiviral Res. 2008 Nov;80(2):87-93. doi: 10.1016/j.antiviral.2008.06.010. Epub 2008 Jul 9. Review.

20.

Antibody-dependent enhancement of dengue virus infection is inhibited by SA-17, a doxorubicin derivative.

Ayala-Nuñez NV, Jarupathirun P, Kaptein SJ, Neyts J, Smit JM.

Antiviral Res. 2013 Oct;100(1):238-45. doi: 10.1016/j.antiviral.2013.08.013. Epub 2013 Aug 28.

PMID:
23994499
Items per page

Supplemental Content

Write to the Help Desk